Adjuvant Radiotherapy After Prostatectomy for High-Risk Prostate Cancer
Surgery can remove the prostate and provide valuable pathological information, yet some men remain at substantial risk of recurrent prostate cancer. Adverse findings may include extracapsular extension, positive surgical margins, seminal vesicle invasion, high-grade disease, or detectable prostate-specific antigen (PSA) after the operation. These features prompt discussion about whether radiation should be delivered immediately or reserved for an early rise in PSA.
Adjuvant radiotherapy means treatment given after prostatectomy before biochemical recurrence is documented. The decision is more nuanced than simply identifying a “high-risk” label. It involves pathology, PSA kinetics, urinary recovery, sexual function, age, other illnesses, expected life span, and the likely benefit of adding androgen deprivation therapy. Australian patients may also need to consider access to a radiation oncology service, public or private waiting times, and travel from regional areas to centres in Sydney, Melbourne, Brisbane, Perth, Adelaide, or other major cities.
Identifying A Meaningful Recurrence Risk
Pathology provides the foundation for postoperative treatment planning. A positive margin means cancer cells reach the inked edge of the removed specimen, while extracapsular extension indicates that the tumour has grown beyond the prostate capsule. Seminal vesicle invasion and Grade Group 4 or 5 disease generally indicate a greater chance of relapse. Lymph-node involvement changes the discussion further, as systemic therapy may become an important component.
PSA should become undetectable or very low after prostate removal because the prostate is no longer present. A persistent PSA suggests residual disease, whereas a later, confirmed rise is usually described as biochemical recurrence. Modern ultrasensitive PSA tests can detect very small changes, but clinicians interpret trends carefully rather than reacting to one isolated result.
Australian practice commonly involves review by a multidisciplinary team that may include a urologist, radiation oncologist, pathologist, radiologist, and medical oncologist. Men should receive a clear explanation of the pathology report and the expected value of treatment in their specific case. Second opinions can be particularly useful when margins are positive, PSA remains detectable, or the proposed plan includes long-term hormone therapy.
Timing Radiation After Surgery
Earlier practice often favoured routine radiation for men with adverse pathology, even when PSA was undetectable. More recent randomised evidence supports close PSA surveillance with early salvage radiotherapy for many patients. This approach avoids exposing every high-risk man to urinary, bowel, and sexual side effects when some would never develop a recurrence.
The RADICALS-RT, RAVES, and GETUG-AFU 17 trials, considered together in the ARTISTIC meta-analysis, did not show a clear event-free survival advantage for routine adjuvant treatment over a policy of early salvage treatment. However, the findings do not mean that adjuvant radiotherapy is never appropriate. Men with persistent PSA, very aggressive pathology, extensive nodal disease, or a particularly high predicted relapse risk may still be advised to start treatment promptly.
The practical distinction is important. Adjuvant therapy begins when PSA is undetectable, while salvage therapy begins after PSA becomes detectable or rises. Salvage treatment works best when delivered at a low PSA level, so surveillance must be organised rather than passive. A clinician may recommend PSA testing every three to six months initially, with the exact schedule adjusted to risk and recovery.
| Feature | Adjuvant Radiotherapy | Early Salvage Radiotherapy |
|---|---|---|
| Usual trigger | High-risk pathology with undetectable PSA | Confirmed detectable or rising PSA |
| Main advantage | Treats possible microscopic disease before a measured recurrence | Avoids treatment for men who may never relapse |
| Main limitation | May overtreat some men and affect recovery | Requires reliable PSA monitoring and rapid referral |
| Typical discussion | Positive margins, seminal vesicle invasion, very high-grade disease | PSA persistence or early biochemical recurrence |
| Hormone therapy | Considered according to risk and imaging | Considered according to PSA, pathology, nodes, and imaging |
Planning The Radiation Course
Radiotherapy usually targets the prostate bed, where recurrent microscopic cancer is most likely to appear. If lymph nodes are involved or the recurrence risk is very high, the radiation field may include pelvic nodes. Magnetic resonance imaging, pathology review, and selected molecular or genomic tests may help refine the plan, although access and funding vary.
Contemporary external-beam radiation uses image guidance and intensity modulation to shape the dose around the target. Treatment is delivered over multiple outpatient visits, with the number of fractions depending on the centre, the treatment field, and the chosen schedule. Stereotactic approaches are being studied in selected postoperative settings but are not appropriate for every patient.
Androgen deprivation therapy may be added when the risk of distant or nodal disease is significant. It can cause hot flushes, reduced libido, erectile difficulties, fatigue, mood changes, loss of muscle mass, and metabolic effects. The duration should be explained clearly, because a short course and long-term hormonal suppression have very different implications for daily life.
Patients in Australia may receive treatment through public hospitals, private radiation centres, or integrated cancer services. The Australian Government’s Medicare arrangements influence access to medical consultations and tests, while out-of-pocket expenses can still arise through private care, medicines, transport, and time away from work. Radiation facilities operate within Australian radiation safety requirements, including standards overseen by the Australian Radiation Protection and Nuclear Safety Agency and relevant state or territory regulators.
Managing Urinary, Bowel, And Sexual Effects
Recovery from prostatectomy should be assessed before radiation whenever circumstances allow. Urinary leakage may improve gradually with pelvic-floor rehabilitation, and radiotherapy can aggravate urgency, frequency, or weak flow. A continence assessment helps distinguish expected recovery from infection, bladder-neck narrowing, or another treatable problem.
Bowel symptoms can include looser stools, urgency, rectal discomfort, mucus, or occasional bleeding. Modern planning reduces exposure to the rectum and bowel, but previous bowel disease, haemorrhoids, and baseline bowel habits still matter. Radiation teams can provide dietary and medication advice, while persistent bleeding should be investigated rather than assumed to be a routine treatment effect.
Erectile function is often affected by surgery, radiotherapy, hormone therapy, or the combination. Early discussion allows access to pelvic-floor therapy, phosphodiesterase-5 inhibitors, vacuum devices, injections, or other services when appropriate. Australian men may find that continence products, private allied-health appointments, and sexual rehabilitation are handled differently across states and health systems, so referral should be arranged before problems become entrenched.
Daily habits also influence recovery. Regular walking, resistance exercise, maintaining a healthy waistline, moderating alcohol, stopping smoking, and limiting highly processed foods support cardiovascular and metabolic health. These measures do not replace cancer treatment, but they can help manage fatigue and the longer-term effects of androgen deprivation.
Following PSA And New Evidence
After treatment, PSA remains the central surveillance tool. A slowly rising result may lead to repeat testing, imaging, and discussion of salvage treatment, while a rapid increase can indicate a greater likelihood of disease outside the prostate bed. PSMA PET-CT is increasingly used in Australia when PSA rises, although a negative scan does not exclude microscopic disease and availability may differ between metropolitan and regional services.
Follow-up should also cover blood pressure, cholesterol, glucose, bone health, mood, sexual wellbeing, and exercise capacity, particularly when hormone therapy is prescribed. Vitamin D and calcium advice, weight-bearing activity, and bone-density assessment may be relevant for men receiving prolonged androgen deprivation. Coordination between the GP, urologist, radiation oncologist, and oncology team reduces duplicated tests and missed symptoms.
Evidence continues to develop around genomic classifiers, pelvic-node irradiation, treatment intensification, and shorter radiation schedules. Clinicians and patients can review peer-reviewed urological research through current and past issues, where studies on prostate cancer, urinary symptoms, and treatment outcomes provide broader clinical context. Research findings should be interpreted alongside Australian guidelines, local expertise, and the individual pathology report rather than applied as a universal rule.
For men and families seeking reliable specialist information, the urological research platform offers access to scientific content from the Taiwan Urological Association’s journal. It can support informed discussions, but personal treatment decisions still require review by the clinicians responsible for the patient’s care.
Discuss the pathology, PSA schedule, radiation field, expected side effects, hormone therapy, and financial or travel implications with the treating team. A documented surveillance plan and rapid referral for a confirmed PSA rise give eligible Australian patients the best opportunity to receive effective postoperative treatment at the right time.